Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force
dc.check.date | 2018-05-29 | |
dc.check.info | Access to this article is restricted until 12 months after publication by request of the publisher. | en |
dc.contributor.author | Manning, Jennifer | |
dc.contributor.author | Buckley, Maria M. | |
dc.contributor.author | O'Halloran, Ken D. | |
dc.contributor.author | O'Malley, Dervla | |
dc.contributor.funder | University College Cork | en |
dc.contributor.funder | Muscular Dystrophy Ireland | |
dc.date.accessioned | 2017-08-24T09:26:48Z | |
dc.date.available | 2017-08-24T09:26:48Z | |
dc.date.issued | 2017-05-29 | |
dc.date.updated | 2017-08-24T09:14:02Z | |
dc.description.abstract | Introduction: Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration leading to immobility, respiratory failure, and premature death. As chronic inflammation and stress are implicated in DMD pathology, the efficacy of an anti-inflammatory and anti-stress intervention strategy in ameliorating diaphragm dysfunction was investigated. Methods: Diaphragm muscle contractile function was compared in wild-type and dystrophin-deficient mdx mice treated with saline, anti-interleukin-6 receptor antibodies (xIL-6R), the corticotrophin-releasing factor receptor 2 (CRFR2) agonist, urocortin 2, or both xIL-6R and urocortin 2. Results: Combined treatment with xIL-6R and urocortin 2 rescued impaired force in mdx diaphragms. Mechanical work production and muscle shortening was also improved by combined drug treatment. Conclusions: Treatment which neutralizes peripheral IL-6 signaling and stimulates CRFR2 recovers force-generating capacity and the ability to perform mechanical work in mdx diaphragm muscle. These findings may be important in the search for therapeutic targets in DMD. | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Accepted Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.citation | Manning, J., Buckley, M. M., O'Halloran, K. D. and O'Malley, D. (2017) 'Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force', Muscle and Nerve. doi:10.1002/mus.25644 | en |
dc.identifier.doi | 10.1002/mus.25644 | |
dc.identifier.endpage | 7 | en |
dc.identifier.issn | 0148-639X | |
dc.identifier.issn | 1097-4598 | |
dc.identifier.journaltitle | Muscle and Nerve | en |
dc.identifier.startpage | 1 | en |
dc.identifier.uri | https://hdl.handle.net/10468/4521 | |
dc.language.iso | en | en |
dc.publisher | John Wiley & Sons, Inc. | en |
dc.rights | © 2017, Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Manning, J., Buckley, M. M., O'Halloran, K. D. and O'Malley, D. (2017) 'Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force', Muscle and Nerve, which has been published in final form at http://dx.doi.org/10.1002/mus.25644. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. | en |
dc.subject | Corticotrophin-releasing factor | en |
dc.subject | Diaphragm | en |
dc.subject | Interleukin-6 | en |
dc.subject | mdx | en |
dc.subject | Monoclonal | en |
dc.subject | Urocortin 2 | en |
dc.title | Combined xIL-6R and urocortin-2 treatment restores mdx diaphragm muscle force | en |
dc.type | Article (peer-reviewed) | en |